BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Five Clinical Presentations Highlight Shionogi Pharma, Inc.'s PSD502, an Investigational Treatment for Primary Premature Ejaculation


5/26/2010 10:19:51 AM

ATLANTA, May 26 /PRNewswire/ -- Shionogi Pharma, Inc., a U.S.-based group company of Shionogi & Co., Ltd.,announced today that the investigational new drug PSD502, a topical metered dose spray which is being developed for the treatment of primary premature ejaculation (PE), will be the subject of five clinical presentations early next month. These data will be presented at the American Urological Association's (AUA) 2010 Annual Meeting May 29 to June 3 in San Francisco.

The times, titles and lead authors of the data presentations follow.



Date/Time

Presentation Title

Lead Author




June 01, 2010

8:40 8:50AM PT


An integrated summary of the results of two pivotal phase III studies of PSD502 for premature ejaculation (PE)

Ira D. Sharlip, MD, University of California at San Francisco, San Francisco, CA




June 01, 2010

8:50 9:00AM PT


Does time matter? Determination of the relationship between increasing ejaculatory latency in men with premature ejaculation and the domains of the index of premature ejaculation (IPE)

Stanley E. Althof, PhD, University of Miami Miller School of Medicine, West Palm Beach, FL




June 01, 2010

11:10 11:20AM PT


PSD502: A second phase III, randomized, double-blind, placebo-controlled study in premature ejaculation (PE) patients in the US and Europe

Culley C. Carson, MD, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC




June 01, 2010

11:20 11:30AM PT


PSD502 appears to be effective in both circumcised and un-circumcised men with premature ejaculation (PE)

Wayne Hellstrom, MD, FACS, Tulane University School of Medicine, New Orleans, LA




June 01, 2010

1:50 2:00PM PT


Efficacy is maintained and may be enhanced using long-term (1yr) administration of PSD502 for premature ejaculation (PE)

Michael A. Perelman, PhD, New York Presbyterian Hospital, New York, NY





About Premature Ejaculation (PE)

For years, experts debated about the definition of premature ejaculation. In 2008, the International Society for Sexual Medicine presented an evidence-based definition of PE as agreed upon by a consensus of the world's leading sexual health experts: a male sexual dysfunction characterized by ejaculation which always or nearly always occurs prior to or within about one minute of vaginal penetration; and inability to delay ejaculation on all or nearly all vaginal penetrations; and negative personal consequences, such as distress, bother, frustration and/or the avoidance of sexual intimacy.

About Shionogi & Co., Ltd.

Headquartered in Osaka, Japan, Shionogi & Co., Ltd. is a major research-driven pharmaceutical company dedicated to placing the highest value on patients. Shionogi's Research and Development currently targets three therapeutic areas: Infectious Diseases, Pain, and Metabolic Syndrome. The Company has provided such innovative medicines as Crestor and doripenem, which have been successfully delivered to millions of patients. In addition, Shionogi is engaged in new research areas such as allergy and cancer. Contributing to the health of patients around the world through development in these therapeutic areas is Shionogi's primary goal. For more details, please visit www.shionogi.co.jp. For more information on Shionogi Pharma, Inc. based in Atlanta, Georgia, please visit www.shionogipharma.com.

SOURCE Shionogi Pharma, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES